Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

N/ANo Longer AvailableNCT01949766

University of Pittsburgh

Overview

This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

Study Type

EXPANDED_ACCESS

Conditions

Byler Disease

Interventions

Glycerol phenylbutyrateDRUG

Eligibility

Sex: ALLMin age: 6 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Byler Disease * Cholestasis * Tolerance of Buphenyl therapy Exclusion Criteria: * Allergy/Hypersensitivity to RAVICTI

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.